Cancer Res (2023) 83 (7_Supplement): ND02.

1 Department of Medicine and Pathology, College of Physicians and Surgeons, Columbia University, and the Presbyterian Hospital, New York City ...

Abstract. Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: an EBCTCG meta-analysis of individual patient data from 12 randomised ...

Cancer Res (2022) 82 (12_Supplement): 3595. Combination treatment with RMC-6291 and SHP2 or SOS1 inhibitors was well tolerated in preclinical models and further increased anti-tumor activity, likely ...

1Department of Oncology, University of Lausanne, Lausanne, Switzerland.

Department of Pharmacology and Toxicology, Otago School of Medical Sciences, University of Otago, Dunedin, New Zealand. *Corresponding Author: John C. Ashton, University of Otago, Frederick Street, ...

1Surveillance, Prevention, and Health Services Research, American Cancer Society, Atlanta, Georgia. *Corresponding Author: Elizabeth J. Schafer, Surveillance ...

Background:. A critical component of oncogenesis and cancer progression is metabolic re-programming of cells to enable continuous growth. Oncogenic activated signaling pathways can drive de novo ...

1Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Centre of Montpellier, Montpellier, France.

1Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Solna, Sweden. *Corresponding Author: David P. Lane, Department of Microbiology, Tumor and ...

1Office of the Report on Carcinogens, Division of the National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina. *Corresponding Author: ...

1Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. 2Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, The Ohio State University, ...